November 30, 2016 - By Clifton Ray
They currently have a GBX 450.00 PT on Synthomer (LON:SYNT). Deutsche Bank’s target would suggest a potential upside of 24.31% from the company’s previous close. This was revealed to investors in a research note on 30 November.
Out of 14 analysts covering Synthomer (LON:SYNT), 5 rate it a “Buy”, 2 “Sell”, while 7 “Hold”. This means 36% are positive. GBX 450 is the highest target while GBX 260 is the lowest. The GBX 370.93 average target is 1.13% above today’s (GBX 366.8) stock price. Synthomer has been the topic of 77 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The company was maintained on Wednesday, October 14 by HSBC. The firm has “Underperform” rating by Credit Suisse given on Tuesday, August 23. As per Wednesday, November 9, the company rating was maintained by Peel Hunt. Barclays Capital maintained Synthomer PLC (LON:SYNT) rating on Monday, September 28. Barclays Capital has “Overweight” rating and GBX 360 price target. The firm has “Hold” rating given on Monday, November 9 by Numis Securities. The company was maintained on Thursday, October 15 by Deutsche Bank. The firm earned “Hold” rating on Wednesday, November 9 by N+1 Singer. Deutsche Bank maintained the stock with “Buy” rating in Thursday, March 3 report. The firm has “Sell” rating given on Wednesday, September 14 by UBS. On Friday, January 15 the stock rating was maintained by JP Morgan with “Neutral”.
About 126,110 shares traded hands. Synthomer PLC (LON:SYNT) has risen 3.16% since May 2, 2016 and is uptrending. It has underperformed by 2.07% the S&P500.
Analysts await Syntel, Inc. (NASDAQ:SYNT) to report earnings on February, 16. They expect $0.55 earnings per share, down 37.50% or $0.33 from last year’s $0.88 per share. SYNT’s profit will be $45.08M for 8.82 P/E if the $0.55 EPS becomes a reality. After $0.63 actual earnings per share reported by Syntel, Inc. for the previous quarter, Wall Street now forecasts -12.70% negative EPS growth.
Insitutional Activity: The institutional sentiment increased to 1.17 in 2016 Q2. Its up 0.07, from 1.1 in 2016Q1. The ratio is positive, as 27 funds sold all Synthomer PLC shares owned while 55 reduced positions. 24 funds bought stakes while 66 increased positions. They now own 28.31 million shares or 0.38% less from 28.42 million shares in 2016Q1.
Eulav Asset, a New York-based fund reported 22,700 shares. Barclays Public Lc, a United Kingdom-based fund reported 7 shares. Springbok Mgmt Limited Liability, a New York-based fund reported 2,500 shares. Jensen Management reported 9,660 shares or 0.01% of all its holdings. Cim Limited accumulated 10,947 shares or 0.25% of the stock. Commercial Bank Of America De has invested 0% of its portfolio in Synthomer PLC (LON:SYNT). Rk Asset Mgmt Limited Liability Co accumulated 7.58% or 187,582 shares. Boston Family Office Lc has 0.41% invested in the company for 69,191 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 679 shares for 0% of their US portfolio. Blair William & Il has 23,145 shares for 0.01% of their US portfolio. Bb&T Ltd Liability Corp holds 0.01% or 11,268 shares in its portfolio. Morgan Stanley holds 0% or 7,406 shares in its portfolio. Moreover, Renaissance Grp Inc Lc has 0.01% invested in Synthomer PLC (LON:SYNT) for 6,133 shares. Independent Consultants holds 12,060 shares or 0.17% of its portfolio. Usa Fincl Portformulas accumulated 0.34% or 27,520 shares.
Insider Transactions: Since August 22, 2016, the stock had 3 buys, and 23 selling transactions for $682,805 net activity. $58,331 worth of Synthomer PLC (LON:SYNT) shares were bought by Doeke Thomas. Rakesh Nitin also sold $73,511 worth of Synthomer PLC (LON:SYNT) shares. Reddy Murlidhar also sold $16,408 worth of Synthomer PLC (LON:SYNT) on Tuesday, August 30. Jain Anil had sold 1,250 shares worth $56,994 on Monday, August 22. 20,000 shares were bought by CHOKSI PARITOSH K, worth $389,964 on Monday, November 21. Mason Christopher had sold 500 shares worth $10,274 on Wednesday, October 26. $146,514 worth of Synthomer PLC (LON:SYNT) was sold by Ranade Prashant on Monday, August 22.
Synthomer Plc is a United Kingdom-based specialty chemical company. The company has a market cap of 1.25 billion GBP. The Firm supplies lattices and specialty emulsion polymers for markets, including paper and board, constructions and coatings, health and protection, functional polymers, performance polymers, and carpet, compounds and foam. It has a 15.84 P/E ratio. It operates in divisions, including Europe and North America and Asia and Rest of World (ARW).
According to Zacks Investment Research, “Syntel is a worldwide provider of advanced technology services to Fortune 1000 companies, as well as to government entities. Their service offerings are grouped into three segments: e-Business, Application Outsourcing, and Teamsourcing. E-Business consists of practice areas in Web Solutions, Customer Relationship Management, Data Warehousing/Business Intelligence, and Enterprise Application Outsourcing services.”
Syntel, Inc. (Syntel), incorporated on April 15, 1980, is a global well-known provider of digital transformation, information technology (IT) and knowledge process outsourcing (KPO) services. The Firm operates through five divisions: Banking and Financial Services, Healthcare and Life Sciences, Insurance, Manufacturing, and Retail, Logistics and Telecom. The Firm offers its services and products under the Syntel brand.
Another recent and important Synthomer PLC (LON:SYNT) news was published by Fool.Co.Uk which published an article titled: “3 Big Winners: Shire plc, Synthomer plc & Evraz plc. Should You Buy Or Sell Today?” on March 21, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray